---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-013066"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T12:04:40.490991+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xencor appoints Nancy Valente as EVP, Chief Development Officer; board reduced to 7

## Summary
- Nancy Valente appointed EVP and Chief Development Officer effective May 1, 2023; she resigned from board.
- Valente previously SVP at Genentech/Roche; led development of GAZYVA, VENCLEXTA, POLIVY, HEMLIBRA.
- Compensation: $540K base salary, 50% bonus target, option grant for 235,778 shares ($3.9M), RSU grant of 39,269 shares ($1.3M).
- Allen Yang steps down as executive officer effective May 1 but stays in non-executive role.
- Board size reduced from 8 to 7 to eliminate vacant seat left by Valente.

## SEC filing metadata
- accession: 0001628280-23-013066
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000162828023013066/0001628280-23-013066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000162828023013066/xncr-20230424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-013066
- JSON: https://secwatch.observer/filing/0001628280-23-013066.json
- Plain text: https://secwatch.observer/filing/0001628280-23-013066.txt

## Key facts
- Executive change
  Nancy Valente resigned as Director at Xencor Inc.
  - Action: resigned
  - Role: Director
  source text: Dr. Nancy Valente tendered her offer of resignation from the Board of Directors (the "Board") of Xencor, Inc. (the "Company"), subject to the Board's acceptance of her resignation. Also on April 24, 2023, the Board accepted Dr. Valente's resignation, effective as of May 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326732/000162828023013066/0001628280-23-013066-index.htm
- Executive change
  Allen Yang changed role as executive officer at Xencor Inc.
  - Action: stepped down
  - Role: executive officer
  source text: Dr. Allen Yang will step down from his role as an executive officer of the Company. He will continue to be employed by the Company in a non-executive capacity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326732/000162828023013066/0001628280-23-013066-index.htm
- Executive change
  Nancy Valente was appointed as Executive Vice President and Chief Development Officer at Xencor Inc.
  - Action: appointed
  - Role: Executive Vice President and Chief Development Officer
  source text: Dr. Nancy Valente, age 64, was appointed as Executive Vice President and Chief Development Officer of the Company, effective May 1, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326732/000162828023013066/0001628280-23-013066-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.